However, given that acquired resistance and adverse events (e.g., acute anemia and thrombocytopenia) have been observed in systemic CD47/CD24 antibody administration58,59, the feasibility of blocking CD47/CD24 alone or in combination in GBM remains uncertain. This evidence concerns the gene CD24 and Thrombocytopenia.